相关实验视频
Updated: Jun 1, 2025

08:48
Author Spotlight: Decoding Mitochondrial Aging
Published on: June 30, 2023
3.6K
阿尔茨海默病中的线粒体功能障碍:指导目标治疗的道路
Kyle C McGill Percy1, Zunren Liu1, Xin Qi2
1Department of Physiology & Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
概括
线粒体功能障碍和质量控制受损是阿尔茨海默病 (AD) 神经退行的主要驱动因素. 恢复线粒体健康为减缓AD进展提供了有希望的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β斑块和团,导致神经退行.
- 线粒体功能障碍越来越被认为是AD病变发生的中心因素.
- 线粒体质量控制 (MQC) 对于维持细胞健康和功能至关重要.
研究的目的:
- 审查MQC的分子通路及其在AD中的作用.
- 突出最近关于神经退行过程中的线粒体机制的发现.
- 探索针对AD中线粒体功能障碍的治疗策略.
主要方法:
- 关于MQC中的分子通路的文献综述.
- 对阿尔茨海默病病理相关性的分析.
- 对线粒体功能障碍的治疗干预措施的探索.
主要成果:
- 干扰MQC过程 (蛋白质稳定,动力学,线粒,器官通信) 有助于AD.
- 损坏的MQC导致生物能衰竭,神经炎症和AD中的脂质失衡.
- 线粒体功能障碍加剧了阿尔茨海默病的神经退行.
结论:
- 在AD病变发生过程中,MQC通路至关重要.
- 准线粒体功能障碍为AD提供了新的治疗途径.
- 恢复线粒体功能对于缓解AD发病和进展至关重要.
更多相关视频
相关概念视频
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Electron Transport Chain: Complex I and II
10.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.8K
Mitochondria
10.2K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
10.2K
Parkinson's Disease: Overview
456
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
456
Parkinson's Disease: Treatment
202
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
202

